Tue. 11 Jun 2024, 8:21am ET
Benzinga
Biotech, News, General
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months
At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable disease (SD)
For all NGC-Cap doses, 5-Fluorouracil (5-FU) exposure was greater and fluoro-beta-alanine (FBAL) exposure was lower with a better or similar side-effect profile than monotherapy capecitabine